Young S L, Ho Y S, Silbajoris R A
Department of Medicine, Durham Veterans Affairs Hospital, North Carolina.
Am J Physiol. 1991 Feb;260(2 Pt 1):L161-7. doi: 10.1152/ajplung.1991.260.2.L161.
The distribution of the major surfactant apoprotein (SP-A) in adult rat lung was determined in order to gain insight into its metabolism, including packaging of SP-A into lamellar bodies. The effect of glucocorticoid treatment on surfactant apoprotein was studied to test whether regulation of surfactant apoprotein genes, which has been described for the fetal lung, can be demonstrated in the adult animal. We measured the amounts of immunoreactive SP-A in several lung tissue compartments and lavage fractions from control animals and from the lungs of rats given dexamethasone for 1 wk. Protein and phospholipids were measured, SP-A was quantitated with a noncompetitive enzyme-linked immunoabsorbent assay (ELISA) and SP-A, SP-B, and SP-C mRNAs were estimated by Northern blotting. We found an 85-fold concentration of SP-A in a lamellar body-rich fraction compared with lung tissue homogenate and we calculated that as much as one-half of all the tissue SP-A might be accounted for by a lamellar body pool. After 1 wk of dexamethasone treatment, there was an increase in adult rat lung SP-A, SP-B, and SP-C mRNA and a substantial increase in tissue and lavage fluid immunoreactive SP-A pools. Lamellar body fraction SP-A content per lung was 1.4-fold higher after dexamethasone, and there was a fivefold increase in the lavage SP-A pool, much of which was inseparable from the alveolar macrophages. We conclude that SP-A is concentrated in the lamellar bodies of type II cells, that dexamethasone treatment increased all surfactant mRNAs, and that it increased SP-A content in adult rat lung.
为了深入了解主要表面活性物质载脂蛋白(SP-A)在成年大鼠肺中的代谢情况,包括其包装到板层小体中的过程,我们测定了其在成年大鼠肺中的分布。研究了糖皮质激素治疗对表面活性物质载脂蛋白的影响,以测试在成年动物中是否能证明已在胎儿肺中描述的表面活性物质载脂蛋白基因的调控情况。我们测量了对照动物以及给予地塞米松1周的大鼠肺中几个肺组织区室和灌洗组分中免疫反应性SP-A的含量。测定了蛋白质和磷脂含量,用非竞争性酶联免疫吸附测定法(ELISA)对SP-A进行定量,并通过Northern印迹法估计SP-A、SP-B和SP-C mRNA的含量。我们发现与肺组织匀浆相比,富含板层小体的组分中SP-A的浓度高85倍,并且我们计算出所有组织SP-A中多达一半可能由板层小体池构成。地塞米松治疗1周后,成年大鼠肺中SP-A、SP-B和SP-C mRNA增加,组织和灌洗液中免疫反应性SP-A池大幅增加。地塞米松治疗后,每只肺的板层小体组分中SP-A含量高1.4倍,灌洗SP-A池增加了5倍,其中大部分与肺泡巨噬细胞不可分离。我们得出结论,SP-A集中在II型细胞的板层小体中,地塞米松治疗增加了所有表面活性物质mRNA,并且增加了成年大鼠肺中SP-A的含量。